A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase 2, Dose[1]Ranging Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SPR720 as Compared with Placebo for the Treatment of Patients with Mycobacterium avium Complex (MAC) Pulmonary Disease

Phase: 2

Status: Ongoing

Details

The purpose of this study is to learn how well the study drug works compared with placebo; how safe and tolerable the study drug is compared with placebo; and to check the amount of study drug in the body.

Sponsor: Spero Therapeutics, Inc.

NCT05496374 - IRB#2023-024

Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top